The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.本発明は、Sykキナーゼの阻害剤である、式Iの化合物ならびにその医薬的に許容される塩、エステル、およびプロドラッグに関する。本発明はまた、該化合物の製造において用いられる中間体、該化合物の製造法、該化合物を含む医薬組成物、Sykキナーゼ活性の阻害方法、血小板凝集の阻害方法、ならびに、少なくとも一部はSykキナーゼ活性により媒介される多くの症状（非ホジキンリンパ腫を含む）を予防もしくは処置する方法に関する。
